Hosted by Sarah Mitchell & James Carter
Downloads
More from: Heart Failure Deep Dive Series
Sarah Mitchell & James Carter
Sarah Mitchell & James Carter
Sarah Mitchell & James Carter
- Quadruple therapy (ARNi + beta-blocker + MRA + SGLT2i) reduces CV death/hospitalisation by ~73% vs placebo in HFrEF
- SGLT2 inhibitors carry Class I, Level A recommendation in HFrEF regardless of diabetes status
- STRONG-HF: rapid co-initiation at low doses with early follow-up outperforms slow sequential titration
- Clinical inertia - not evidence gaps - is the primary barrier to optimal HFrEF management
Cite This Article
Team TLSFE. How four drugs beat heart failure. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/cardiology/heart-failure/insights/how-four-drugs-beat-heart-failure.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Podcast Disclaimer
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
[1] McMurray JJV et al. PARADIGM-HF. N Engl J Med. 2014;371:993-1004
[2] McMurray JJV et al. DAPA-HF. N Engl J Med. 2019;381:1995-2008
[3] Packer M et al. EMPEROR-Reduced. N Engl J Med. 2020;383:1413-1424
[4] Vaduganathan M et al. Lancet. 2020;396:121-128
[5] Mebazaa A et al. STRONG-HF. Lancet. 2022;400:1938-1952
